Regenerative Medicine Market to Reach $30,237 Million, Globally, by 2022 - Allied Market Research - Seite 2

Biologically derived materials, such as collagen and xenogeneic, are majorly applicable in the construction of protein membranes in connective tissues, surgical procedures for valvular diseases, liver tissue engineering, construction of biopolymer scaffolds for tissue engineering, and others. The growing demand for these biologically derived materials further boosts the market growth. The biologically derived material segment accounted for the major share in 2015, whereas, the synthetic material is expected to grow at a significant CAGR of 35.5% during the forecast period.

Musculoskeletal and wound healing application together accounted for over 60% share of the total market in 2015. Cell therapies are mostly utilized for the treatment of musculoskeletal diseases such as a bone tissue replacement, cartilage, and tendon and ligament repair & replacement. In addition, osteoporosis is one of the most prevalent disease that requires tissue engineering, and more than 75 million people suffer from osteoporosis in Europe, U.S., and Japan; thus increasing the demand for regenerative medicine.

Geographically, North America accounted for the majority of the market share in 2015, and is expected to maintain its lead throughout. This is attributed to the presence of higher capital investment, high disposable income of patients (increasing the buying potential), rise in clinical studies, and favorable government policies for the commercialization of tissue engineering and regenerative medicine products. However, Asia-Pacific is projected to be the fastest growing region, owing to the improving healthcare infrastructure and healthcare expenditures in the emerging markets (such as India and China) to overcome the unmet medical needs. In addition, tissue engineering and regenerative medicine market is growing substantially due to the increasing incidence of accidental trauma injuries in this region. Increasing incidences of injuries and the ageing population also contributes to the market growth.

Key findings of Regenerative Medicines Market:

• Biologically derived materials led the market, accounting for almost four-sevenths of the overall market revenue in 2015, and is projected to grow at a CAGR of 31.6% during the forecast period.
• Scaffold in synthetic material segment is expected to grow at a CAGR of 42.4%, owing to the degradation properties and bioabsorbable polymer, which acts as a bone fixation device.
• U.S. is projected to maintain its lead in the regenerative medicine market until 2022.
• Musculoskeletal and wound healing applications together accounted for around 60% of the overall market shares in 2015.
• China and Japan are the major shareholders, jointly accounting for almost two-thirds in the Asia-Pacific market.
• The collagen segment constitutes a major share of the biologically derived materials market.
• Three-dimensional polymer technology is anticipated to grow at fastest rate, with a CAGR of 44% from 2016 to 2022.

Key players in the regenerative medicine market are highly focused on expanding their business operations in the emerging countries with new product launches as a preferred strategy. Leading players profiled in the report include Stryker Corporation, Zimmer Biomet Holdings, Inc., Medtronic plc, Baxter International Inc., DePuy Synthes, Organogenesis Inc. (Advanced Biohealing), Integra Lifesciences Holdings Corporation, Acelity Holdings, Inc., Ocata Therapeutics Inc. (Astellas Pharma Inc.), and CryoLife Inc.